# Xanodyne Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xanodyne-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Newport, US
- Website: www.xanodyne.com
- Total disclosed funding: $253M
- Latest round: Series D (Jun 4, 2009)
- Investors on record: 8

## About

Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare.

## Funding rounds

- Series D, Jun 4, 2009, $38M — Blue Chip Venture Company, Essex Woodlands, HealthCare Ventures, Aisling Capital, MPM BioImpact, American International Group, Inc., Union Springs Pharmaceuticals
- Series A, Jul 27, 2007, $25M — Apax Partners, Blue Chip Venture Company, Essex Woodlands, HealthCare Ventures, Aisling Capital, Union Springs Pharmaceuticals
- Series A, Jul 1, 2005, $170M — Apax Partners, Blue Chip Venture Company, Essex Woodlands, HealthCare Ventures, Aisling Capital, Union Springs Pharmaceuticals
- Series C, Jun 1, 2004, $20M — Blue Chip Venture Company, Essex Woodlands, HealthCare Ventures

## Investors

- Blue Chip Venture Company (https://capitalatlas.ai/funds/blue-chip-venture-company) — Series C, Series A, Series D
- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series C, Series A, Series D
- HealthCare Ventures — Series C, Series A, Series D
- Apax Partners (https://capitalatlas.ai/funds/apax-partners) — Series A
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series A, Series D
- Union Springs Pharmaceuticals — Series A, Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series D
- American International Group, Inc. — Series D